Skip to main content

Knight Therapeutics Inc(GUD-T)
TSX

Today's Change
Real-Time Last Update
Day Low5.72
Day High5.83
Open:5.83
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
GlobeNewswire
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
Baystreet
Stocks in play: Knight Therapeutics Inc.,
GlobeNewswire
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
GlobeNewswire
Knight Therapeutics Inc. Celebrates its First Decade of Success
GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
GlobeNewswire
Knight Therapeutics Announces Launch of Bijuva® in Canada
GlobeNewswire
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
GlobeNewswire
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Knight Therapeutics Reports Third Quarter 2023 Results
GlobeNewswire
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
GlobeNewswire
Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Knight Therapeutics Reports Second Quarter 2023 Results
GlobeNewswire
Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call
Baystreet
Stocks in play: Knight Therapeutics Inc.
GlobeNewswire
Knight Announces Normal Course Issuer Bid
The Globe and Mail
Knight Therapeutics: Stocks Analysts Recently Downgraded on TSX (GUD)

Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.